U.S. Markets open in 3 hrs 43 mins
  • S&P Futures

    3,936.00
    +19.75 (+0.50%)
     
  • Dow Futures

    31,607.00
    +120.00 (+0.38%)
     
  • Nasdaq Futures

    12,220.00
    +79.50 (+0.65%)
     
  • Russell 2000 Futures

    1,770.80
    +9.10 (+0.52%)
     
  • Crude Oil

    107.29
    -0.33 (-0.31%)
     
  • Gold

    1,840.70
    +10.40 (+0.57%)
     
  • Silver

    21.50
    +0.37 (+1.75%)
     
  • EUR/USD

    1.0581
    +0.0022 (+0.2116%)
     
  • 10-Yr Bond

    3.1250
    0.0000 (0.00%)
     
  • Vix

    28.20
    -0.85 (-2.93%)
     
  • GBP/USD

    1.2294
    +0.0025 (+0.2004%)
     
  • USD/JPY

    135.0800
    -0.0900 (-0.0666%)
     
  • BTC-USD

    21,446.47
    +42.30 (+0.20%)
     
  • CMC Crypto 200

    468.00
    +14.11 (+3.11%)
     
  • FTSE 100

    7,267.42
    +58.61 (+0.81%)
     
  • Nikkei 225

    26,871.27
    +379.30 (+1.43%)
     

Do Insiders Own Lots Of Shares In Reata Pharmaceuticals, Inc. (NASDAQ:RETA)?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

Reata Pharmaceuticals has a market capitalization of US$1.3b, so we would expect some institutional investors to have noticed the stock. Taking a look at our data on the ownership groups (below), it seems that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Reata Pharmaceuticals.

View our latest analysis for Reata Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Reata Pharmaceuticals?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Reata Pharmaceuticals. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Reata Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. Reata Pharmaceuticals is not owned by hedge funds. Our data shows that CPMG, Inc. is the largest shareholder with 13% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 12% and 8.7%, of the shares outstanding, respectively. William Rose, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. In addition, we found that J. Huff, the CEO has 1.8% of the shares allocated to their name.

On further inspection, we found that more than half the company's shares are owned by the top 7 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Reata Pharmaceuticals

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Our information suggests that insiders maintain a significant holding in Reata Pharmaceuticals, Inc.. It has a market capitalization of just US$1.3b, and insiders have US$157m worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 14% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Reata Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For example, we've discovered 2 warning signs for Reata Pharmaceuticals that you should be aware of before investing here.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.